Search Press releases Keywords From To 14 Nov 2022 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients Read More 10 Nov 2022 Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Read More 8 Nov 2022 UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022 Read More 13 Oct 2022 UCB announces positive preliminary results for major brivaracetam (Briviact[®]) study in Asia Read More 27 Sep 2022 FINTEPLA[®▼] (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome Read More 23 Sep 2022 Disposal of own shares Read More Pagination First page Previous page Previous … Page 21 Page 22 Page 23 Page 24 Current page 25 Page 26 Page 27 Page 28 Page 29 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe